<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170918036261N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-11-28</date_registration>
      <primary_sponsor>Vice chancellor for research Babol University of Medical Sciences</primary_sponsor>
      <public_title>The effect of yarrow vaginal cream on treatment of candida vaginitis</public_title>
      <acronym></acronym>
      <scientific_title>The comparision effect of Achillea millefolium products on traditional medicine base, with clotrimazole cream 1% on vaginal candidiasis.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27161</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The method of randomization in this study is quadruple blocking method and the randomization unit is individual and tool is statistical software. The sequencing will be done by quadruple blocking. Concealing done by using simillar form and size tubes for both groups, and neither the interventions nor the volunteers nor the data analyzer knows how to allocate the intervention, Blinding description: In this study, patients are completely unaware of which drugs they received. Also, the investigator and data analyzer are completely unaware that the two groups received which drug.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Candida vulvovaginitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Vaginal cream 2% of aqueous extract of Achillea millefolium, one applicator at night for 7 nights. Made in Pharmacy Department of Traditional Medicine, College of Traditional Medicine, Babol University of Medical Science. Intervention 2: Control group: Vaginal cream of clotrimazol 1% made by the PARS DAROU pharmaceutical company; Tehran, IRAN. One applicator at night for 7 nights.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Somaye Zakerii</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Babol Traditional Medicine College, Babol Univesity of Medical Sciences, Ganjafrooz Street, Karwgar Squar, Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>46159-73899</zip>
        <telephone>+98 11 4308 3172</telephone>
        <email>www.drzakerii@yahoo.com</email>
        <affiliation>Babol Univesity of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Doctor Nargess Gorji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Babol Traditional Medicine college, Babol University of Medical Sciences, Ganjafrooz street, Karegar Square</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۴۷۱۷۶-۴۷۷۴۵</zip>
        <telephone>+98 11321995926</telephone>
        <email>www.nargess_girji@yahoo.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>married women,18 to 45 years old
The presence of sign and symptoms of candida vulvovaginitis
Positive smear from vaginal discharge for candida
Positive culture of vaginal discharge for candida</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of allergy to clotrimazole vaginal cream
History of drug allergy
Pregnancy
Mensturation period
Breastfeeding
Menopause
The presence of chronic underlying diseases: kidney, liver and Heart diseases, Diabetes and Immune deficiency
Score 24-30 based on DLQI questionnaire
Vulvar erythem score 3
Use of systemic antibiotics, immunosuppressive drugs or other vaginal creams and antifungal drugs during the past 4 weeks
Patient's unsatisfactory to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B37.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Candidiasis of vulva and vagina</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Vaginal cream 2% of aqueous extract of Achillea millefolium, one applicator at night for 7 nights. Made in Pharmacy Department of Traditional Medicine, College of Traditional Medicine, Babol University of Medical Science</i_keyword>
      <i_keyword>Control group: Vaginal cream of clotrimazol 1% made by the PARS DAROU pharmaceutical company; Tehran, IRAN. One applicator at night for 7 nights.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Burning. Timepoint: At first, 7-10 days after the beginning of interventon and 2-3 weeks after the end of intervention. Method of measurement: Evauation of clinical symptom's remission (burning) with Dermatology Quality of Life Index (DLQI ) questionnaire.</prim_outcome>
      <prim_outcome>Pruritus. Timepoint: At first, 7-10 days after the begining of interventon and 2-3 weeks after the end of intervention. Method of measurement: Evauation of clinical symptom's remission (pruritus) with Dermatology Quality of Life Index (DLQI ) questionnaire.</prim_outcome>
      <prim_outcome>Dysparonia. Timepoint: At first, 7-10days after the begining of interventon and 2-3 weeks at the end of intervention. Method of measurement: Evauation the rate of satisfactory from intercourse  with  Dermatology Quality of Life Index (DLQI ) questionnaire.</prim_outcome>
      <prim_outcome>Volvar erythema. Timepoint: At first, 7-10days after the begining of interventon and 2-3 weeks at the end of intervention. Method of measurement: Vulvar examination and scoring the erythema of vulva by Gynecologist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Result of culture. Timepoint: At first, 7-10 days after the begining of intervention and 2-3 weeks after the end of intervention. Method of measurement: Sampling from vaginal discharges.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-08-27</approval_date>
        <contact_name>Ethics committee of Babol University of Medical Science</contact_name>
        <contact_address>karegar squar., Ganjafrooz street., Babol University of Medical Science., Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
